AI is your drugs’ new KOL—and you’re not tracking it.
That’s the uncomfortable truth buried in the latest DrugPatentWatch post: as artificial intelligence becomes embedded in how clinicians, researchers, and even patients find information, it’s quietly…

Most companies don’t miss the patent—they miss the money.
Drug patents don’t expire in a vacuum. They expire inside a competitive timeline: payer negotiations, formulary decisions, manufacturing lead times, and—most importantly—commercial strategy. Yet…

Drug patent expiry isn’t a calendar event—it’s a portfolio risk model. Here’s how to forecast it by country.
If you manage a pharma portfolio, you already know the uncomfortable truth: patent expiry dates don’t just determine when exclusivity ends. The…

Generic entry is rarely about the molecule. It’s about the manufacturing.
If you’ve spent any time around pharma strategy, you’ve probably heard the same refrain: “The patent cliff is coming.” But the real cliff for many companies isn’t the active ingr…

Biotech IPOs can feel like a clean bet: a compelling pipeline, a credible management team, and a market hungry for the next breakthrough. But in life sciences, “breakthrough” doesn’t matter if the patent foundation is shaky—or if the clock is already r…

Biosimilar entry windows aren’t just math—they’re risk management. And the companies that treat them like a spreadsheet exercise keep paying for it.
In a recent piece from DrugPatentWatch, the focus is blunt: there are costly mistakes companies make wh…

Most teams don’t lose on science—they lose on timing.
In generic and biosimilar development, the difference between a “go” and a “no-go” decision often comes down to one question: What does the patent landscape actually say, and what does it mean for…

Designing Around the Moat: How Generic Developers Can Win the Secondary-Formulation Game
The patent “moat” around a blockbuster drug is rarely just one wall. It’s a layered fortress—primary composition claims, method-of-use claims, manufacturing proces…

Pharma doesn’t just “own” patents—it engineers time.
In a world where blockbuster revenues are increasingly squeezed by generic competition, the real battleground is often not the original patent grant. It’s the calendar. The ability to extend exclusiv…

Your pharmaceutical portfolio may have a time bomb in it—and patent expiration data is the fuse.
If you’re leading strategy, BD, or portfolio management, you already know the headline: patents expire, generics arrive, margins compress, and forecasts ge…